• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, May 20

Suven Life Sciences Ltd has secured two product patents in South Africa and China for two of its New Chemical Entities for the treatment of disorders associated with neuro-degenerative diseases. The granted claims of the patents, which are valid till 2024 and 2025, respectively, included the class of selective 5-HT compounds discovered by the Hyderabad-based company. The compounds were being developed as therapeutic agents and would be useful in the treatment of cognitive impairment associated with neuro-degenerative disorders such as attention deficient hyperactivity, Alzheimer’s, Parkinson, Schizophrenia and Huntington’s, according to a release.

— Our Bureau

More Stories on : IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Maruti hikes prices

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line